NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

New European Bauhaus

This initiative wants to make a contribution to a more esthetic, inclusive and sustainable way of building in the EU

Your NCP contact for this programme

Image of Man Hei To

Man Hei To

manhei.to@fwo.be

+32 2 550 15 55

About this programme

The New European Bauhaus is a creative and interdisciplinary initiative that connects the European Green Deal to our living spaces and experiences.

Click to read more 
Hide text 

Upcoming events

No events that are specifically related to New European Bauhaus were found. Check the full calendar.

Work Programme & Calls

We offer a handy Excel file, weekly updated, containing an up-to-date overview of the Horizon Europe calls. call topics overview

Infosheets

Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.

    No infosheets available for this domain

Related links

Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.

Documents

Documents contain additional information related to this programme, and are similar to related links.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.